Basic control of reperfusion effectively protects against reperfusion injury in a realistic rodent model of acute limb ischemia.
BACKGROUND
Reperfusion injury is insufficiently addressed in current clinical management of acute limb ischemia. Controlled reperfusion carries an enormous clinical potential and was tested in a new reality-driven rodent model.


RESULTS
Acute hind-limb ischemia was induced in Wistar rats and maintained for 4 hours. Unlike previous tourniquets models, femoral vessels were surgically prepared to facilitate controlled reperfusion and to prevent venous stasis. Rats were randomized into an experimental group (n=7), in which limbs were selectively perfused with a cooled isotone heparin solution at a limited flow rate before blood flow was restored, and a conventional group (n=7; uncontrolled blood reperfusion). Rats were killed 4 hours after blood reperfusion. Nonischemic limbs served as controls. Ischemia/reperfusion injury was significant in both groups; total wet-to-dry ratio was 159+/-44% of normal (P=0.016), whereas muscle viability and contraction force were reduced to 65+/-13% (P=0.016) and 45+/-34% (P=0.045), respectively. Controlled reperfusion, however, attenuated reperfusion injury significantly. Tissue edema was less pronounced (132+/-16% versus 185+/-42%; P=0.011) and muscle viability (74+/-11% versus 57+/-9%; P=0.004) and contraction force (68+/-40% versus 26+/-7%; P=0.045) were better preserved than after uncontrolled reperfusion. Moreover, subsequent blood circulation as assessed by laser Doppler recovered completely after controlled reperfusion but stayed durably impaired after uncontrolled reperfusion (P=0.027).


CONCLUSIONS
Reperfusion injury was significantly alleviated by basic modifications of the initial reperfusion period in a new in vivo model of acute limb ischemia. With this model, systematic optimizations of according protocols may eventually translate into improved clinical management of acute limb ischemia.
Dick
Florian
F
Department of Cardiovascular Surgery, Inselspital, and University of Bern, Berne, Switzerland.
Li
Jianhui
J
Giraud
Marie-Noëlle
MN
Kalka
Christoph
C
Schmidli
Juerg
J
Tevaearai
Hendrik
H
D000208:Acute Disease; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D004195:Disease Models, Animal; D004487:Edema / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000502:physiology / Q000601:surgery; D006493:Heparin / Q000494:pharmacology; D006614:Hindlimb / Q000098:blood supply*; D017078:Laser-Doppler Flowmetry; D008297:Male; D009119:Muscle Contraction; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D054070:Postthrombotic Syndrome / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow; D015427:Reperfusion Injury / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control*; D014111:Tourniquets; D014463:Ultrasonography
D000925:Anticoagulants; D006493:Heparin